Nectar Lifesciences Limited (NSE: NECLIFE | BSE: 532649)
Source: Nectar Lifesciences Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Nectar Lifesciences Limited (“NLL” or “Neclife”) was historically established as an integrated pharmaceutical company with a core specialisation in the cephalosporin segment of active pharmaceutical ingredients (APIs) and finished dosage formulations. Over nearly three decades, the company established large-scale manufacturing infrastructure in Punjab and Himachal Pradesh, supplying domestic drug manufacturers and exporting oral and sterile APIs and dosage forms across multiple continents.
- Active Pharmaceutical Ingredients (APIs) & Intermediates: Oral and sterile cephalosporin active ingredients, including Cefixime, Cefuroxime Axetil, Cefpodoxime Proxetil, Ceftriaxone, Cefotaxime, and Cefepime, produced at Derabassi Units 1 and 2.
- Finished Dosage Formulations: Oral solid dosage forms (tablets, dry syrups, and capsules) manufactured at the Unit 6 formulation facility in Baddi, Himachal Pradesh.
- Empty Hard Gelatin Capsules (EHGC): Specialized capsule manufacturing situated at Village Bhatoli Kalan, Dharmpur, Baddi, HP (under definitive sale agreement to Capnest Health Care).
- Menthol Derivative Assets: Dedicated processing capacity for natural menthol and related aromatic chemical products.
📋 Quick Facts / Company Snapshot: Nectar Lifesciences Limited (NSE: NECLIFE | BSE: 532649)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Nectar Lifesciences Limited |
| Corporate Identity Number (CIN) | L21000PB1995PLC016664 |
| ISIN | INE023H01027 |
| Stock Exchange Listing | NSE: NECLIFE | BSE: 532649 |
| Date of Incorporation / Founding Year | June 27, 1995 |
| Founders / Key Founding Figures | Mr. Sanjiv Goyal |
| Registered Office | Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab – 140507, India |
| Corporate Headquarters / Correspondence Address | 110, Industrial Area, Phase 1, Chandigarh – 160002, India |
| Official Investor Relations Email | cs@neclife.com |
| Chairman & Managing Director | Mr. Sanjiv Goyal |
| Chief Financial Officer (CFO) | Mr. Sushil Kapoor (Whole-time Director & CFO) |
| Company Secretary & Compliance Officer | Mr. Sanjaymohan Singh Rawat |
| Promoter & Holding Group | Mr. Sanjiv Goyal and Sanjiv (HUF) |
| Industry / Sector Classification | Pharmaceuticals / Real Estate Activities (Amended Objects) |
| Total Employees / Permanent Workforce | 111 permanent employees (as on March 31, 2026) |
| Manufacturing Plants / Facilities Mentioned | Unit 1 & Unit 2 (Derabassi, Punjab – Divested), Unit 6 (Baddi, Himachal Pradesh – Divested), Capsule Unit (Bhatoli Kalan, Baddi, HP – Held for Sale), Jammu Unit (Inoperative – Held for Sale) |
| Credit Ratings & Rating Agency | CARE Ratings Limited (FY 2024-25: Long-Term CARE BB, Short-Term CARE A4+; FY 2025-26: Not applicable / No borrowings outstanding) |
| Statutory Auditors | M/s Deepak Jindal & Co., Chartered Accountants (Firm Regn No. 023023N) |
| Secretarial Auditor | Mr. Prince Chadha, M/s P. Chadha & Associates, Company Secretaries |
| Cost Auditor | Cost audit conducted up to FY 2025-26; not applicable from FY 2026-27 onward due to cessation of manufacturing |
| Registrar and Share Transfer Agent (RTA) | KFin Technologies Limited, Selenium Tower B, Plot No. 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500032 |
🏢 The Corporate Identity: Nectar Lifesciences Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Nectar Lifesciences Limited (“NLL” or “Neclife”) was historically established as an integrated pharmaceutical company with a core specialisation in the cephalosporin segment of active pharmaceutical ingredients (APIs) and finished dosage formulations. Over nearly three decades, the company established large-scale manufacturing infrastructure in Punjab and Himachal Pradesh, supplying domestic drug manufacturers and exporting oral and sterile APIs and dosage forms across multiple continents.
Facing increasing regulatory requirements, technological shifts, and substantial legacy operating challenges that culminated in consecutive years of operating losses, Nectar Lifesciences executed a fundamental strategic restructuring during the financial year ended March 31, 2026. The company reached a structural turning point by divesting its active pharmaceutical ingredients and formulations operations, rationalising its industrial footprint, settling debt obligations in full, and amending its corporate charter to pivot into the real estate sector.
The Founders, Promoters & Their Legacy
The promoter and entrepreneurial leader behind NLL is Mr. Sanjiv Goyal, a commerce and law graduate who initiated business activities by setting up a proprietary concern in Chandigarh in 1987. Mr. Goyal incorporated NLL on June 27, 1995, and has guided its strategic direction as Chairman and Managing Director since its inception.
Over a leadership career extending 37 years across business development, project execution, and corporate finance, Mr. Goyal navigated the enterprise from an Indian cephalosporin manufacturer through various capital-raising phases and extensive capacity additions. During FY 2025-26, faced with significant industry pressures and corporate stress, Mr. Goyal and the promoter group orchestrated a liquidity and asset-realisation program to de-risk the balance sheet, retiring term debt and working capital obligations.
The Journey: Corporate History & Key Milestones
The corporate evolution of Nectar Lifesciences spans three distinct decades of industrial development, regulatory approvals, operational scaling, and asset restructuring:
- 1995: Incorporation of Nectar Lifesciences Limited under the Companies Act, 1956, commencing cephalosporin manufacturing.
- 2005: Public listing of equity shares on both the BSE Limited and the National Stock Exchange of India Limited.
- 2019: Establishment of an international footprint via the incorporation of wholly owned subsidiary Neclife PT, Unipessoal LDA in Portugal.
- 2021: Implementation of a debt restructuring resolution framework with lead commercial lenders to manage operational working capital stress.
- July 7, 2025: Execution of a definitive Business Transfer Agreement (BTA) to transfer the core Pharma Businesses (Unit 1 & Unit 2 at Derabassi, Punjab, and Unit 6 at Baddi, Himachal Pradesh) to Ceph Lifesciences Private Limited on a going concern slump-sale basis, alongside an Asset Purchase Agreement (APA) for menthol business assets.
- August 4, 2025: Approval of the Pharma Businesses slump sale by shareholders via a special resolution at an Extraordinary General Meeting.
- November 10, 2025: Closure and financial settlement of the slump sale of Pharma Businesses for an adjusted consideration of ₹1,253.99 Crores, yielding an exceptional gain of ₹163.37 Crores, and transfer of Menthol Assets for ₹20.00 Crores.
- December 20, 2025: Signing of a BTA with Capnest Health Care Private Limited for the slump sale of the Empty Hard Gelatin Capsule business in Baddi, HP, for ₹19.90 Crores.
- January 2026: Completion of a tender-offer buyback of 3,00,00,000 equity shares of face value ₹1 each at ₹27 per share, extinguishing ₹3.00 Crores of share capital and deploying ₹0.81 Crores in cash.
- February 28, 2026: Member approval via postal ballot to amend the Objects Clause of the Memorandum of Association, formally introducing real estate activities.
- March 6, 2026: Acquisition of 100% equity share capital of Avensis Exports Private Limited (AEPL) for ₹0.25 Crores, establishing it as a wholly owned vehicle to lead the company’s real estate initiatives.
The Corporate Umbrella & Group Structure
Following the strategic corporate reorganisations completed during FY 2025-26, the corporate structure of NLL comprises the listed parent entity along with two wholly owned subsidiaries:
- Nectar Lifesciences Limited (Parent): Listed corporate vehicle, formerly operating the active pharmaceutical ingredients and formulation units, now directing capital allocation toward monetization of surplus properties and real estate opportunities.
- Avensis Exports Private Limited (AEPL): An Indian wholly owned subsidiary acquired on March 6, 2026, for a consideration of ₹0.25 Crores, into which NLL infused an inter-corporate loan of ₹98.00 Crores during FY 2025-26 to explore and develop real estate ventures.
- Neclife PT, Unipessoal LDA: A wholly owned overseas subsidiary incorporated in Portugal on July 11, 2019, carrying an investment book value of €1,000, which has remained non-operational with negligible financial balances.
⚙️ The Business Engine: Nectar Lifesciences Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Historically, the company operated as a single reportable primary business segment: “Pharmaceutical Products”, encompassing APIs, intermediates, finished dosage formulations, menthol, and hard gelatin capsules. In accordance with Ind AS 105, operations associated with the transferred business undertakings have been classified and reported as “Discontinued Operations”, leaving continuing operations with nil operating manufacturing revenue for FY 2025-26.
Gross sales from discontinued operations during the period of operational activity prior to closing stood at ₹470.98 Crores (inclusive of GST) in FY 2025-26, compared to ₹1,908.40 Crores in FY 2024-25. The summary breakdown of segmental performance is as follows:
| Segment Name | FY 2025-26 (₹ in Crores) | % Share of Total Revenue | FY 2024-25 (₹ in Crores) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|---|
| Continuing Operations (Real Estate / Corporate) | 0.00 | 0.00% | 0.00 | 0.00% | N/M |
| Discontinued Operations (Pharmaceutical Products)* | 470.98 | 100.00% | 1,908.40 | 100.00% | -75.32% |
| Total Gross Sales (inclusive of GST) | 470.98 | 100.00% | 1,908.40 | 100.00% | -75.32% |
*Gross sales inclusive of GST derived from discontinued operations prior to the slump sale date. Under Ind AS Schedule III, net revenue from continuing operations on the face of the P&L is presented as ₹0.00 Crores for both years.
The Product & Service Catalog
Prior to the slump sale, Nectar Lifesciences developed, synthesized, and commercialized a broad portfolio centered primarily on third- and fourth-generation cephalosporin antibiotics, along with specialized capsule shells:
- Active Pharmaceutical Ingredients (APIs) & Intermediates: Oral and sterile cephalosporin active ingredients, including Cefixime, Cefuroxime Axetil, Cefpodoxime Proxetil, Ceftriaxone, Cefotaxime, and Cefepime, produced at Derabassi Units 1 and 2.
- Finished Dosage Formulations: Oral solid dosage forms (tablets, dry syrups, and capsules) manufactured at the Unit 6 formulation facility in Baddi, Himachal Pradesh.
- Empty Hard Gelatin Capsules (EHGC): Specialized capsule manufacturing situated at Village Bhatoli Kalan, Dharmpur, Baddi, HP (under definitive sale agreement to Capnest Health Care).
- Menthol Derivative Assets: Dedicated processing capacity for natural menthol and related aromatic chemical products.
- Real Estate & Property Development: Following the postal ballot amendment of February 28, 2026, the company entered real estate development, property acquisition, Joint Development Agreements (JDAs), and mixed-use commercial and residential land projects.
The Names You Know: Key Business Platforms & Units
The operational landscape of Nectar Lifesciences was structured across specialized manufacturing platforms that formed the subject of the corporate asset transactions:
| Brand / Operating Platform | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Derabassi Manufacturing Facility (Units 1 & 2) | Bulk Drugs / Cephalosporin APIs | Large-scale oral and sterile bulk active manufacturing for domestic supply and global exports (Transferred to Ceph Lifesciences). |
| Baddi Formulation Facility (Unit 6) | Finished Dosage Formulations | Solid oral dosage forms catering to domestic pharma brands and tender supplies (Transferred to Ceph Lifesciences). |
| Baddi Capsule Undertaking (Village Bhatoli Kalan) | Empty Hard Gelatin Capsules (EHGC) | Specialised two-piece capsule shells supplied to domestic pharmaceutical encapsulation lines (Under BTA with Capnest Health Care). |
| Avensis Exports Private Limited | Real Estate Activities | Wholly owned subsidiary focused on land acquisitions, redevelopment, and real estate project execution. |
Mapping the Domestic & Global Reach (India vs. Exports)
During the period of operational activity in FY 2025-26 prior to the transfer of the industrial plants, Nectar Lifesciences exported its manufactured products to 32 countries across Asia, Africa, Latin America, and Europe. In secondary geographical segment disclosures, revenue split was as follows:
| Geographical Market | FY 2025-26 (₹ in Crores) | % Share of Total Gross Sales | FY 2024-25 (₹ in Crores) | % Share of Total Gross Sales | Latest YoY (%) |
|---|---|---|---|---|---|
| India (Domestic Market) | 302.17 | 64.16% | 1,171.58 | 61.39% | -74.21% |
| Outside India (Exports) | 168.81 | 35.84% | 736.82 | 38.61% | -77.09% |
| Total Gross Sales (inclusive of GST) | 470.98 | 100.00% | 1,908.40 | 100.00% | -75.32% |
Total actual foreign exchange earned through inward remittances during FY 2025-26 stood at ₹242.77 Crores, compared to a total foreign exchange outgo (including equity buyback distributions and import payments) of ₹359.52 Crores.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The physical footprint of the company underwent structural changes during the fiscal year:
- Unit 1 & Unit 2 (Derabassi, SAS Nagar, Punjab): The historical flagship bulk drug chemical synthesis complex for cephalosporin APIs; ownership transferred to Ceph Lifesciences on November 10, 2025.
- Unit 6 (Baddi, District Solan, Himachal Pradesh): Oral solid dosage formulation facility; transferred to Ceph Lifesciences on November 10, 2025.
- Capsule Manufacturing Facility (Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, HP): Dedicated manufacturing plant for Empty Hard Gelatin Capsules; carrying value classified under Assets Held for Sale (₹20.88 Crores assets, ₹4.06 Crores associated liabilities) pending statutory clearances.
- Jammu Industrial Facility (Jammu, J&K): Inoperative manufacturing facility with Property, Plant and Equipment of ₹1.76 Crores classified under Assets Held for Sale.
- Garhshankar Land Parcel (Village Dallewal, Garhshankar, Punjab): Non-core vacant freehold land measuring ₹13.22 Crores designated for monetization, a portion of which was sold subsequent to March 31, 2026.
- Corporate & Registered Offices: Registered office at Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Punjab; Corporate correspondence office at 110, Industrial Area, Phase 1, Chandigarh.
📊 The Financial Health: Nectar Lifesciences Financial Statements & Numbers Simplified
The audited Consolidated Financial Statements of Nectar Lifesciences Limited for the fiscal year ended March 31, 2026, reflect the accounting implications of the slump sale of the Pharma Businesses, asset impairment recognitions, debt retirement, equity share buyback, and entry into real estate.
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
Under Indian Accounting Standards, the ongoing operations of NLL reflect corporate investment holdings and real estate activities, while the manufacturing operations are accounted for under Discontinued Operations.
| Particulars (Statement of Profit and Loss) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Continuing Operations | |||
| Revenue from Operations (Gross) | 0.00 | 0.00 | N/M |
| Less: GST Recovered | 0.00 | 0.00 | N/M |
| Revenue from Operations (Net of GST) | 0.00 | 0.00 | N/M |
| Other Income (Net) | 9.29 | 1.88 | +394.15% |
| Total Income (Continuing Operations) | 9.29 | 1.88 | +394.15% |
| Expenses | |||
| Raw Material Consumed | 0.00 | 0.00 | N/M |
| Purchase of Stock in Trade | 0.00 | 0.00 | N/M |
| (Increase) / Decrease in Inventories | 0.00 | 0.00 | N/M |
| Employee Benefits Expense | 1.91 | 0.09 | +2022.22% |
| Finance Cost | 36.13 | 0.00 | N/M |
| Depreciation & Amortization Expense | 0.34 | 0.62 | -45.16% |
| Other Expenses | 58.79 | 0.10 | +58690.00% |
| Total Expenses (Continuing Operations) | 97.17 | 0.81 | +11896.30% |
| Profit / (Loss) Before Tax from Continuing Operations | (87.88) | 1.07 | N/M |
| Tax Expenses relating to Continuing Operations | (30.53) | 0.38 | N/M |
| Profit / (Loss) After Tax from Continuing Operations | 292.89 | 0.70 | +41741.43% |
| Discontinued Operations | |||
| Profit / (Loss) from Discontinued Operations Before Tax | (537.66) | (162.61) | +230.64% |
| Exceptional Items (Gain on Slump Sale) | 163.37 | 0.00 | N/M |
| Tax Expense relating to Discontinued Operations | (138.74) | (48.23) | +187.66% |
| Profit / (Loss) from Discontinued Operations After Tax | (235.54) | (114.38) | +105.93% |
| Profit / (Loss) for the Year (Continuing + Discontinued) | (292.89) | (113.68) | +157.64% |
| Other Comprehensive Income | |||
| Items that will not be reclassified to profit or loss: Remeasurement of Net Defined Benefit | 0.12 | 0.83 | -85.54% |
| Income Tax relating to items not reclassified | (0.04) | (0.29) | -86.21% |
| Items that will be reclassified to profit or loss: Foreign Exchange Translation Reserve | 0.00 | 0.00 | N/M |
| Total Other Comprehensive Income for the Year | 0.08 | 0.54 | -85.19% |
| Total Comprehensive Income for the Year | (292.81) | (113.14) | +158.80% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The Consolidated Balance Sheet as of March 31, 2026, reflects the receipt of slump-sale cash consideration, total settlement of institutional bank debt, and an increase in cash and financial assets.
| Particulars (Consolidated Balance Sheet) | As at March 31, 2026 (₹ in Crores) | As at March 31, 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Non-Current Assets | |||
| Property, Plant and Equipment | 103.41 | 576.61 | -82.07% |
| Capital Work-in-Progress | 0.00 | 56.73 | -100.00% |
| Intangible Assets | 0.00 | 56.50 | -100.00% |
| Goodwill on Consolidation | 1.11 | 0.00 | N/M |
| Inventory (Non-Current) | 0.00 | 50.61 | -100.00% |
| Financial Assets: Investments | 0.24 | 0.24 | 0.00% |
| Financial Assets: Trade Receivables | 0.00 | 8.49 | -100.00% |
| Financial Assets: Loans | 0.07 | 0.00 | N/M |
| Financial Assets: Other Financial Assets | 2.93 | 3.25 | -9.85% |
| Deferred Tax Assets (Net) | 224.48 | 55.04 | +307.85% |
| Other Non-Current Assets | 0.56 | 2.17 | -74.19% |
| Total Non-Current Assets | 332.78 | 809.64 | -58.90% |
| Current Assets | |||
| Inventory | 0.30 | 690.16 | -99.96% |
| Financial Assets: Current Investments | 12.97 | 0.53 | +2347.17% |
| Financial Assets: Trade Receivables | 0.00 | 345.49 | -100.00% |
| Financial Assets: Cash and Cash Equivalents | 112.14 | 19.22 | +483.45% |
| Financial Assets: Loans | 0.09 | 0.86 | -89.53% |
| Financial Assets: Other Financial Assets | 66.00 | 7.51 | +778.83% |
| Other Current Assets | 61.47 | 173.82 | -64.64% |
| Total Current Assets | 252.97 | 1,237.59 | -79.56% |
| Assets Held for Sale | 35.85 | 0.00 | N/M |
| TOTAL ASSETS | 621.61 | 2,047.23 | -69.64% |
| Equity | |||
| Equity Share Capital | 19.43 | 22.43 | -13.37% |
| Other Equity | 562.87 | 933.68 | -39.71% |
| Total Equity (Net Worth) | 582.30 | 956.11 | -39.10% |
| Non-Current Liabilities | |||
| Borrowings (Non-Current) | 0.00 | 60.13 | -100.00% |
| Other Financial Liabilities | 9.19 | 0.00 | N/M |
| Provisions (Non-Current) | 0.01 | 8.73 | -99.89% |
| Other Non-Current Liabilities | 0.00 | 0.72 | -100.00% |
| Total Non-Current Liabilities | 9.20 | 69.58 | -86.78% |
| Current Liabilities | |||
| Borrowings (Current) | 0.00 | 521.90 | -100.00% |
| Trade Payables: Micro and Small Enterprises | 0.00 | 8.76 | -100.00% |
| Trade Payables: Other Creditors | 0.00 | 429.36 | -100.00% |
| Other Financial Liabilities (Current) | 25.71 | 49.77 | -48.34% |
| Other Current Liabilities | 0.33 | 8.84 | -96.27% |
| Provisions (Current) | 0.01 | 2.92 | -99.66% |
| Total Current Liabilities | 26.05 | 1,021.54 | -97.45% |
| Liabilities Directly Associated with Assets Held for Sale | 4.06 | 0.00 | N/M |
| Total Liabilities | 39.31 | 1,091.12 | -96.40% |
| TOTAL EQUITY AND LIABILITIES | 621.61 | 2,047.23 | -69.64% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
The asset transfers completed during FY 2025-26 altered the operating and working capital ratios of Nectar Lifesciences:
- Total Borrowings: Long-term and short-term bank borrowings decreased from ₹582.02 Crores as of March 31, 2025, to ₹0.00 Crores as of March 31, 2026, as proceeds from the slump sale were used to extinguish bank liabilities and release pledged promoter shares.
- Trade Receivables & Payables: Operational receivables (₹353.97 Crores as of March 31, 2025) and operational trade payables (₹43.81 Crores as of March 31, 2025) were resolved through transfers to the acquiring entity Ceph Lifesciences or settled, resulting in zero continuing trade receivables and trade payables on the continuing Balance Sheet.
- Interest Coverage & Operating Margin: As explained in the Board’s Report and Note 61 of the Standalone Accounts, standard ratios such as Interest Coverage Ratio and Operating Profit Margin are not meaningful or ascertainable for FY 2025-26 because of the slump sale of the underlying operating pharmaceutical units.
- Return on Net Worth (Return on Average Equity): Stood at -38.08% for FY 2025-26 compared to -11.89% for FY 2024-25. As disclosed in the Management Discussion and Analysis, the negative return widened due to the impact of discontinued business losses and write-downs recognized prior to transfer.
Cash Flow: Tracking the Money Movement
The consolidated cash movement demonstrates the conversion of fixed and working capital assets into liquid funds, retirement of bank debt, capital distribution to shareholders, and liquid treasury deployment:
| Particulars (Consolidated Cash Flow) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Operating Activities | |||
| Profit / (Loss) Before Tax from Continuing Operations | (87.88) | 1.07 | N/M |
| Profit / (Loss) Before Tax from Discontinued Operations | (701.03) | (162.61) | +331.11% |
| Depreciation & Amortization Expense | 22.80 | 62.39 | -63.46% |
| Profit on Slump Sale of Pharma Business | 163.37 | 0.00 | N/M |
| Interest on Borrowings | 36.13 | 74.58 | -51.56% |
| Loss / (Profit) on Sale / Restatement of Investments | 52.10 | (0.04) | N/M |
| Loss / (Profit) on Sale of Fixed Assets | (11.50) | 0.01 | N/M |
| Other Non-Operating Income & Provisions | (28.66) | 2.10 | N/M |
| Operating Profit Before Working Capital Changes | (554.67) | (22.51) | +2364.10% |
| Net Changes in Operating Working Capital Assets and Liabilities | 205.95 | 191.95 | +7.29% |
| Net Cash Flow from Operating Activities (A) | (348.72) | 169.44 | N/M |
| Investing Activities | |||
| Purchase of Fixed Assets (CapEx) | 12.27 | 43.80 | -71.99% |
| Purchase of Investments | (398.95) | 0.00 | N/M |
| Sale of Investments | 334.41 | 0.00 | N/M |
| Sale of Fixed Assets | 20.46 | 0.01 | +204500.00% |
| Cash Acquired on Acquisition of Subsidiary (Net of Consideration) | 3.24 | 0.00 | N/M |
| Proceeds from Slump Sale of Pharma Business | 1,253.99 | 0.00 | N/M |
| Interest & Other Non-Operating Receipts Received | 7.28 | 1.86 | +291.40% |
| Net Cash Flow from Investing Activities (B) | 1,208.15 | (41.93) | N/M |
| Financing Activities | |||
| Proceeds / (Repayment) of Bank Term Loans | (128.18) | (81.28) | +57.70% |
| Proceeds / (Repayment) of Working Capital Limits from Banks | (440.22) | 28.00 | N/M |
| Proceeds / (Repayment) of Loans from Directors / Other Parties | (80.36) | 0.00 | N/M |
| Repayment of Vehicle Loans | (0.63) | (0.23) | +173.91% |
| Buy-back of Equity Shares | (81.00) | 0.00 | N/M |
| Interest Paid | (36.13) | (74.58) | -51.56% |
| Net Cash Flow Used in Financing Activities (C) | (766.51) | (128.09) | +498.42% |
| Net Increase / (Decrease) in Cash and Cash Equivalents (A + B + C) | 92.91 | (0.58) | N/M |
| Cash and Cash Equivalents at Beginning of the Year | 19.22 | 19.81 | -2.98% |
| Cash and Cash Equivalents at End of the Year | 112.14 | 19.22 | +483.45% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Capital management during the year was defined by portfolio divestments rather than new industrial asset creation:
- Fixed Asset Additions: Additions to Property, Plant and Equipment amounted to ₹106.97 Crores, which included freehold land and site development of ₹99.96 Crores acquired on consolidation of subsidiary AEPL, alongside motor vehicles of ₹2.32 Crores and machinery additions of ₹4.15 Crores.
- Capital Work-in-Progress (CWIP): Derecognized to ₹0.00 Crores as of March 31, 2026, from ₹56.73 Crores in the previous year, as suspended projects were divested or closed.
- R&D Expenditure: Total research and development expenditure during the period stood at ₹4.51 Crores (compared to ₹16.22 Crores capitalized in the previous period). Given the divestment of active pharmaceutical manufacturing, dedicated drug R&D programs ceased by the third quarter of FY 2025-26.
- Foreign Exchange Balances: Inward foreign exchange remittances totaled ₹242.77 Crores, against foreign exchange outgoings of ₹359.52 Crores (including payments associated with the equity share buyback).
👥 Power & Control: Nectar Lifesciences Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The Board of Directors of Nectar Lifesciences Limited as of March 31, 2026, comprised six directors, balancing executive promoter leadership, independent academic/technical governance, and corporate oversight:
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Sanjiv Goyal | Chairman & Managing Director | 00002841 | Promoter & Executive Director |
| Mr. Sushil Kapoor | Director (Finance) & Chief Financial Officer (CFO) | 00063525 | Non-Promoter & Executive Director |
| Dr. Rupinder Tewari | Independent Director | 07009485 | Non-Executive & Independent Director |
| Dr. Kuldip Kumar Bhasin | Independent Director | 09250008 | Non-Executive & Independent Director |
| Dr. Indu Pal Kaur | Independent Director | 09686862 | Non-Executive & Independent Director |
| Dr. Surulichamy Senthilkumar | Director | 11124083 | Non-Independent & Non-Executive Director |
| Mr. Sanjaymohan Singh Rawat | Company Secretary & Compliance Officer | N.A. | Key Managerial Personnel (w.e.f. April 1, 2025) |
Directorate changes during FY 2025-26 and up to the reporting date included:
- Mr. Puneet Sud resigned as Whole-time Director (Operations) effective May 31, 2025.
- Dr. Surulichamy Senthilkumar was appointed Whole-time Director (R&D) on June 1, 2025; he stepped down from executive responsibilities on November 10, 2025, upon closure of the Pharma slump sale, continuing as a Non-Executive Director before tendering his board resignation effective August 6, 2026.
- Ms. Meena Verma ceased to be a Nominee Director on October 27, 2025, upon discharge of all liabilities toward the Export-Import Bank of India (EXIM).
- Mr. Sushil Kapoor was elevated from CFO to Additional Director and Whole-time Director [Director (Finance)] on December 4, 2025, approved by postal ballot on February 28, 2026.
- Dr. Gunmala Suri was appointed as an Additional Non-Executive Non-Independent Director effective August 15, 2026.
Who Owns the Stock? Shareholding Pattern
Consequent to the completion of the buyback of 3,00,00,000 equity shares in January 2026, the paid-up share capital stood reduced to 19,42,60,970 equity shares of ₹1 each. The shareholding pattern as of March 31, 2026, was as follows:
| Category | Cases (Shareholders) | Number of Shares | % of Total Shares |
|---|---|---|---|
| Promoters & Promoter Group | 3 | 9,14,68,000 | 51.84% |
| Resident Individuals & HUFs | 75,391 | 7,51,11,394 | 38.66% |
| Qualified Institutional Buyers (QIB) | 1 | 77,84,243 | 4.00% |
| Bodies Corporate | 268 | 71,68,783 | 3.69% |
| Non-Resident Indians (NRIs) | 638 | 20,65,245 | 1.06% |
| Foreign Portfolio Investors (FPI) | 10 | 11,70,169 | 0.60% |
| IEPF Authority | 1 | 1,74,580 | 0.08% |
| Trusts | 1 | 65,000 | 0.03% |
| Non-Banking Financial Companies (NBFC) | 1 | 10,000 | 0.00% |
| Mutual Funds | 2 | 4,608 | 0.00% |
| Unclaimed Shares Suspense Account | 1 | 500 | 0.00% |
| Total Issued & Paid-Up Equity Shares | 76,317 | 19,42,60,970 | 100.00% |
Major individual promoter shareholdings within the group comprise:
- Mr. Sanjiv Goyal: 4,78,45,600 equity shares (24.63% of voting capital).
- Sanjiv (HUF): 4,36,22,400 equity shares (22.46% of voting capital).
- Mrs. Raman Goyal: 92,38,448 equity shares (4.76% of voting capital).
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
The details of the company’s subsidiaries as of March 31, 2026, pursuant to Section 129(3) of the Act, are presented below:
| Entity Name | Relationship | Country | % Shareholding | Turnover (₹ in Crores) | Profit / (Loss) After Tax (₹ in Crores) |
|---|---|---|---|---|---|
| Avensis Exports Private Limited | Wholly Owned Subsidiary | India | 100.00% | 0.00 | (0.18) |
| Neclife PT, Unipessoal LDA | Wholly Owned Subsidiary | Portugal | 100.00% | 0.00 | 0.00 |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
Key treasury assets, banking status, and legal dispute provisions across the company include:
- Current Treasury Investments: Quoted mutual funds and ETF investments totaled ₹12.97 Crores, comprising Nippon India Silver ETF holdings of ₹12.97 Crores. During FY 2025-26, the company deployed surplus funds from slump-sale receipts into market securities; subsequent volatility and market corrections generated a net loss on sale/restatement of investments of ₹52.10 Crores.
- Consortium Debt & Credit Ratings: Following the complete repayment of bank facilities (₹582.02 Crores retired during the fiscal year), the company reported zero bank borrowings as of March 31, 2026. Prior year ratings assigned by CARE Ratings (CARE BB for long-term and CARE A4+ for short-term) were not renewed as no debt remained outstanding.
- Contingent Liabilities (Litigated Claims):
- Income Tax Matters under appeal: ₹88.99 Crores.
- Excise & GST Demands under appeal: ₹179.51 Crores (against which ₹2.56 Crores is deposited under protest).
- Service Tax Demands under dispute: ₹0.72 Crores.
- Outstanding Bank Guarantees: ₹0.09 Crores.
- National Green Tribunal (NGT) Interim Compensation Matter: The NGT directed an interim environmental compensation of ₹5.00 Crores; the company appealed before the Supreme Court of India, which stayed the impugned order subject to a 50% deposit (₹2.50 Crores), duly deposited with the Supreme Court Registry on June 18, 2025.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Following the divestment of its pharmaceutical manufacturing business, the company’s operating posture and competitive footing have been restructured:
- Debt-Free Balance Sheet: The complete payoff of ₹582.02 Crores in consortium debt leaves the corporate entity free from debt-servicing obligations and finance costs on legacy borrowings.
- Liquidity Buffer: Cash and cash equivalents of ₹112.14 Crores, together with current receivables from slump-sale consideration of ₹66.00 Crores, provide capital resources to fund property projects without debt financing.
- Real Estate Repositioning: Through Avensis Exports Private Limited (capitalized with an inter-corporate loan of ₹98.00 Crores) and unencumbered landholdings, NLL has positioned itself to participate in land development and commercial projects.
What Could Go Wrong? Key Challenges & Business Risks
As Nectar Lifesciences transitions away from its historical industrial operational base, it faces several transitional risks:
- Absence of Recurring Operating Revenue: With core pharmaceutical operations divested, continuing revenue from operations was ₹0.00 Crores in FY 2025-26, making near-term income dependent on treasury returns and progress in real estate activities.
- Real Estate Project Execution: Real estate development involves specific risks, including land title clearances, delays in local municipal approvals, cyclicality in property markets, and construction cost inflation.
- Litigation Exposures: Substantial unresolved tax disputes (₹179.51 Crores GST/Excise and ₹88.99 Crores Income Tax) and environmental proceedings before the Supreme Court pose potential balance sheet demands should final determinations be adverse.
- Treasury Volatility: As seen by the ₹52.10 Crores loss on mutual fund investments during FY 2025-26, capital deployment in volatile financial assets carries exposure to equity and commodity market swings.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Management’s corporate strategy centers on the commercial launch of its real estate portfolio and rationalisation of remaining legacy properties:
- Real Estate Operations: Leveraging Avensis Exports Private Limited to evaluate land acquisitions, Joint Development Agreements (JDAs), and mixed-use development opportunities in high-growth regional hubs.
- Asset Monetization: Finalising the sale of the Empty Hard Gelatin Capsule facility to Capnest Health Care Private Limited for ₹19.90 Crores upon receipt of approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act.
- Disposal of Non-Core Assets: Executing the sale of plant assets at the inoperative Jammu unit and liquidating remaining vacant land parcels at Garhshankar, Punjab.
The Verdict: Strategic Outlook & Conclusion
Fiscal year 2025-26 marks a structural transition for Nectar Lifesciences Limited. By executing the slump sale of its cephalosporin bulk drug and formulation divisions for ₹1,253.99 Crores, the company resolved legacy operating challenges, retired bank debt, returned ₹0.81 Crores of capital to public shareholders via a buyback, and preserved a net worth of ₹582.30 Crores. The strategic viability of NLL now centers on management’s ability to deploy its cash reserves and develop operational real estate projects that generate recurring operating cash flows.
Frequently Asked Questions (FAQs) About Nectar Lifesciences
Q1: What does Nectar Lifesciences do, and why did it exit the pharmaceutical sector?
Historically, Nectar Lifesciences was an integrated manufacturer of cephalosporin bulk active ingredients (APIs) and oral finished formulations. Due to changing regulatory standards, operational issues from legacy manufacturing infrastructure, and sustained operating losses, the company completed a slump sale of its API and formulation units (Unit 1 & 2 at Derabassi and Unit 6 at Baddi) to Ceph Lifesciences Private Limited in November 2025 for an adjusted consideration of ₹1,253.99 Crores to settle debts and pivot into real estate activities.
Q2: What were Nectar Lifesciences’ revenues and net profit in FY 2025-26?
For FY 2025-26, net revenue from continuing operations was ₹0.00 Crores, alongside other income of ₹9.29 Crores. The company reported a net loss of ₹57.35 Crores from continuing operations and a net loss of ₹235.54 Crores from discontinued operations (inclusive of an exceptional slump-sale gain of ₹163.37 Crores), bringing the total consolidated net loss for the year to ₹292.89 Crores.
Q3: Who are the primary promoters and executive leaders of the company?
The company was founded and is led by Mr. Sanjiv Goyal, who serves as Chairman and Managing Director. The promoter group, comprising Mr. Sanjiv Goyal, Sanjiv (HUF), and Mrs. Raman Goyal, holds 51.84% of total equity share capital. Executive finance leadership is directed by Mr. Sushil Kapoor, Whole-time Director & Chief Financial Officer.
Q4: Where are the company’s remaining assets and properties located?
NLL holds an Empty Hard Gelatin Capsule facility at Baddi, Himachal Pradesh (under an agreement for slump sale to Capnest Health Care for ₹19.90 Crores), an inoperative manufacturing facility in Jammu, and vacant land at Garhshankar, Punjab, alongside corporate offices in Dera Bassi, Punjab, and Chandigarh.
Q5: What is the debt profile, net worth, and liquidity position of Nectar Lifesciences?
As of March 31, 2026, NLL is debt-free, having retired all ₹582.02 Crores of bank borrowings using proceeds from the slump sale. The company reported a consolidated net worth of ₹582.30 Crores, cash and cash equivalents of ₹112.14 Crores, and slump-sale receivables of ₹66.00 Crores.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.neclife.com